Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2020 655
2021 1021
2022 560
2023 297
2024 62

Text availability

Article attribute

Article type

Publication date

Search Results

2,333 results

Results by year

Filters applied: . Clear all
Page 1
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, Kimber C, Monsef I, Wood EM, Lamikanra AA, Roberts DJ, McQuilten Z, So-Osman C, Jindal A, Cryns N, Estcourt LJ, Kreuzberger N, Skoetz N. Iannizzi C, et al. Cochrane Database Syst Rev. 2023 May 10;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub6. Cochrane Database Syst Rev. 2023. PMID: 37162745 Review.
BACKGROUND: Convalescent plasma may reduce mortality in patients with viral respiratory diseases, and is being investigated as a potential therapy for coronavirus disease 2019 (COVID-19). ...SELECTION CRITERIA: We included randomised controlled trials …
BACKGROUND: Convalescent plasma may reduce mortality in patients with viral respiratory diseases, and is being investigated as …
Convalescent Plasma Therapy in Late-State, Severe COVID-19 Infection.
Kumar NR, Karanam VC, Kumar S, Kumar SD. Kumar NR, et al. South Med J. 2023 May;116(5):427-433. doi: 10.14423/SMJ.0000000000001546. South Med J. 2023. PMID: 37137479 Free PMC article. Review.
We investigated the safety and efficacy of convalescent plasma in specifically late-stage (designated as after 2 weeks of hospital admission) severe COVID-19 infection. ...RESULTS: Eight ICU patients received plasma late in the course of COVI …
We investigated the safety and efficacy of convalescent plasma in specifically late-stage (designated as after 2 weeks of hosp …
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, Kimber C, Monsef I, Wood EM, Lamikanra AA, Roberts DJ, McQuilten Z, So-Osman C, Jindal A, Cryns N, Estcourt LJ, Kreuzberger N, Skoetz N. Iannizzi C, et al. Cochrane Database Syst Rev. 2023 Feb 1;2(2):CD013600. doi: 10.1002/14651858.CD013600.pub5. Cochrane Database Syst Rev. 2023. PMID: 36734509 Free PMC article. Updated. Review.
BACKGROUND: Convalescent plasma may reduce mortality in patients with viral respiratory diseases, and is being investigated as a potential therapy for coronavirus disease 2019 (COVID-19). ...SELECTION CRITERIA: We included randomised controlled trials …
BACKGROUND: Convalescent plasma may reduce mortality in patients with viral respiratory diseases, and is being investigated as …
COVID 19 convalescent plasma: Is there still a place for CCP?
Moog R. Moog R. Transfus Apher Sci. 2023 Apr;62(2):103680. doi: 10.1016/j.transci.2023.103680. Epub 2023 Feb 24. Transfus Apher Sci. 2023. PMID: 36870907 Free PMC article. Review.
This approach was also used in the SARS-CoV-2 pandemic when no specific drugs were available for the treatment of the disease. ...Further clinical trials are necessary to define the role of CCP in the treatment of SARS-CoV-2 disease....
This approach was also used in the SARS-CoV-2 pandemic when no specific drugs were available for the treatment of the d …
Convalescent plasma and hyperimmune globulin therapy in COVID-19.
Cagdas D. Cagdas D. Expert Rev Clin Immunol. 2021 Apr;17(4):309-316. doi: 10.1080/1744666X.2021.1894927. Epub 2021 Mar 12. Expert Rev Clin Immunol. 2021. PMID: 33620014 Review.
Introduction: Severe acute respiratory syndrome causing coronavirus SARS-CoV-2 (coronavirus disease 2019 (COVID-19)) has recently resulted in the recent global pandemic. ...This review discusses the current knowledge on CP and HIG therapies used …
Introduction: Severe acute respiratory syndrome causing coronavirus SARS-CoV-2 (coronavirus disease 2019 (COVID- …
A look-back at convalescent plasma to treat COVID-19.
Garraud O, Lacombe K, Tiberghien P. Garraud O, et al. Transfus Apher Sci. 2021 Feb;60(1):103063. doi: 10.1016/j.transci.2021.103063. Epub 2021 Jan 12. Transfus Apher Sci. 2021. PMID: 33478889 Free PMC article. Review. No abstract available.
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy.
Casadevall A, Joyner MJ, Pirofski LA, Senefeld JW, Shoham S, Sullivan D, Paneth N, Focosi D. Casadevall A, et al. Expert Rev Respir Med. 2023 May;17(5):381-395. doi: 10.1080/17476348.2023.2208349. Epub 2023 May 2. Expert Rev Respir Med. 2023. PMID: 37129285 Review.
INTRODUCTION: When the COVID-19 pandemic struck no specific therapies were available and many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. ...However, COVID-19 in immunocompromised patients is a …
INTRODUCTION: When the COVID-19 pandemic struck no specific therapies were available and many turned to COVID-19 …
Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.
Majumder J, Minko T. Majumder J, et al. AAPS J. 2021 Jan 5;23(1):14. doi: 10.1208/s12248-020-00532-2. AAPS J. 2021. PMID: 33400058 Free PMC article. Review.
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide with millions of people at risk in a growing number of count …
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 ( …
Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
Hosseini P, Rahimi H, Najafabadi MM, Ghorbani A, Najafabadi SK, Faridzadeh A, Arabpour J, Khormali E, Deravi N. Hosseini P, et al. Acta Med Indones. 2021 Jan;53(1):86-95. Acta Med Indones. 2021. PMID: 33818411 Free article. Review.
The global widespread mortality after the emergence of SARS-CoV-2 infection in China, has become a critical concern all around the world. Convalescent plasma (CP) therapy is one of the methods elevating the survival rate for COVID-19 …
The global widespread mortality after the emergence of SARS-CoV-2 infection in China, has become a critical concern all …
Evidence-based dosing of convalescent plasma for COVID-19 in future trials.
Rijnders BJA, Huygens S, Mitjà O. Rijnders BJA, et al. Clin Microbiol Infect. 2022 May;28(5):667-671. doi: 10.1016/j.cmi.2022.01.026. Epub 2022 Feb 10. Clin Microbiol Infect. 2022. PMID: 35150881 Free PMC article. Review.
BACKGROUND: Two years into the pandemic, convincing evidence in favour of convalescent plasma (ConvP) as a treatment for coronavirus disease 2019 (COVID-19) is still lacking. ...OBJECTIVES: This study aimed to review available evidence on dosing of Con …
BACKGROUND: Two years into the pandemic, convincing evidence in favour of convalescent plasma (ConvP) as a treatment for coron …
2,333 results

Searches related to "covid convalescent plasma"